Bharat Biotech Covaxin efficacy 77.8 percent, gets CDSCO panel okay
New Delhi: An expert panel of the country's central drugs authority has reviewed and accepted the phase-3 trial data of Bharat Biotech's COVID-19 vaccine Covaxin, sources said on Tuesday.
According to the data submitted by the Hyderabad-based firm, the indigenously developed vaccine has shown 77.8 per cent efficacy in the trial conducted on 25,800 subjects, they said.
The firm had submitted the results of its phase-3 trial efficacy data of Covaxin to the Drugs Controller General of India (DCGI) over the weekend, they added.
The COVID-19 Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) on Tuesday reviewed the data and accepted it. Their recommendations have been sent to the DCGI now, a source said.
Bharat Biotech is also expected to attend a 'pre-submission' meeting on July 23 with the World Health Organisation (WHO), which will take the vaccine-maker closer to a WHO Emergency Use Listing (EUL).
Though the meeting will not be a detailed review on the product, the vaccine-maker will have an opportunity to submit a summary on the overall quality of the jab, according to the WHO.
The information was provided on the WHO website in the Status of COVID-19 Vaccines within WHO EUL-PQ evaluation process document.
Covaxin is one of the three vaccines approved by the DGCI for emergency use and is being deployed in India's COVID-19 vaccination programme.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.